



SciTech Development, LLC

FOR IMMEDIATE RELEASE

SciTech Inventor & Co-Founder Attending ASCO 2019

(GROSSE POINTE FARMS, MI) May 31, 2019 – SciTech Development inventor and co-founder Ralph Parchment, Ph.D. will be attending ASCO 2019 on May 31- June 4, 2019 at McCormick Place in Chicago, Illinois. Briefly, SciTech is a clinical stage biopharmaceutical company with strong clinical Key Opinion Leader (KOL) backing that reformulated the safe and efficacious anticancer agent fenretinide into an intravenous (IV) drug yielding mandated bioavailability resulting in immuno-oncology (IO) and chemotherapeutic effects that produce apoptosis.



SciTech's lead oncology drug product ST-001 is an IND ready, orphan designated drug with an FDA roadmap to an NDA post Phase 1b for multiple cancer indications.

About SciTech Development

SciTech Development, LLC is a clinical stage, biopharmaceutical company that has developed unique nano-delivery systems (SciTech Delivery Vehicle-SDV) to enable intravenous (IV) delivery of water-insoluble drugs. One such challenged drug is fenretinide which has been shown in extensive clinical trials to be a safe and effective anticancer therapy with targeted cancer destroying activity. The combination of the new SDV and fenretinide has led to SciTech's first drug product, ST-001, which holds the promise of improving and saving many lives. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. More information regarding SciTech's nano-delivery technology and fenretinide containing oncology drug product ST-001 is available at <https://www.scitechdevelopment.com/>

For More Information: Earle T. Holsapple, President
SciTech Development, LLC
(313) 938-5517



###